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Abstract 
Background: Cross‑sectional investigations report shorter telomeres in patients with heart failure (HF); however, no 
studies describe telomere length (TL) trajectory and its relationship with HF progression. Here we aimed to investigate 
telomere shortening over time and its relationship to outcomes.
Methods: Our study cohort included 101 ambulatory patients with HF. Blood samples were collected at baseline 
(n = 101) and at the 1‑year follow‑up (n = 54). Using flow‑FISH analysis of circulating monocytes, we simultane‑
ously measured three monocyte subsets—classical  (CD14++CD16−), intermediate  (CD14++CD16+), and nonclassical 
 (CD14+CD16++)—and their respective TLs based on FITC‑labeled PNA probe hybridization. The primary endpoints 
were all‑cause death and the composite of all‑cause death or HF‑related hospitalization, assessed at 2.3 ± 0.6 years. 
All statistical analyses were executed by using the SPSS 15.0 software, and included Student’s t test and ANOVA with 
post hoc Scheffe analysis, Pearson or Spearman rho correlation and univariate Cox regression when applicable.
Results: We found high correlations between TL values of different monocyte subsets:  CD14++CD16+ vs. 
 CD14++CD16−, R = 0.95, p < 0.001;  CD14++CD16+ vs.  CD14+CD16++, R = 0.90, p < 0.001; and  CD14++CD16− vs. 
 CD14+CD16++, R = 0.89, p < 0.001. Mean monocyte TL exhibited significant attrition from baseline to the 1‑year 
follow‑up (11.1 ± 3.3 vs. 8.3 ± 2.1, p < 0.001). TL did not significantly differ between monocyte subsets at either 
sampling time‑point (all p values > 0.1). Cox regression analyses did not indicate that TL or ΔTL was associated with 
all‑cause death or the composite endpoint.
Conclusions: Overall, this longitudinal study demonstrated a ~ 22% reduction of TL in monocytes from ambulatory 
patients with HF within 1 year. TL and ΔTL were not related to outcomes over long‑term follow‑up.
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Background
Heart failure (HF) has become an epidemic, impos-
ing substantial health, social, and economic bur-
dens. In developed countries, HF affects 1–2% of the 
adult population, with a prevalence of  ≥  10% among 
those ≥  70  years of age [1]. It has been suggested that 
HF is a disease of accelerated aging, and telomere length 
(TL) is proposed as a biomarker of aging [2]. Telomeres 
are specialized and evolutionarily conserved tandem 
repeats (5′-TTA GGG -3′ in humans) located at the end of 
chromosomes. They serve as protective caps that prevent 
the DNA damage-repair system from accidentally iden-
tifying chromosomal ends as DNA double strands [3, 4]. 
Preliminary data from cross-sectional studies reveal that 
persons with HF have shorter telomeres than healthy 
age- and gender-balanced controls, based on analyses of 
circulating leukocytes using a conventional quantitative 
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However, no longitudinal studies have investigated tel-
omere attrition among patients with chronic HF.
TL can also be efficiently assessed in monocytes, a het-
erogeneous population of effector cells that play key roles 
in maintaining and restoring tissue integrity [6]. Using 
flow cytometry, circulating monocytes can be categorized 
into three distinct subsets based on differential expres-
sion levels of the surface markers CD14 and CD16: clas-
sic,  CD14++CD16−; intermediate,  CD14++CD16+; and 
non-classic,  CD14+CD16++ [7]. We recently reported 
TL assessment in monocyte subsets using a novel stand-
ardized analytical protocol based on simultaneous mul-
ticolor flow cytometry-fluorescence in situ hybridization 
(flow-FISH) [8].
In the present article, we report a longitudinal study in 
which we used the novel flow-FISH technique to explore 
the dynamics of telomere attrition in circulating mono-
cytes within a cohort of ambulatory HF patients.
Methods
Study population
Our study cohort included 101 ambulatory patients who 
attended a multidisciplinary HF unit from January 15th 
2014 to May 6th 2015  (Table  1). The referral inclusion 
criteria are described elsewhere [9, 10]. All patients made 
follow-up visits at regular predefined intervals, and addi-
tional visits when required in cases of decompensation. 
The regular visitation schedule included a minimum of 
quarterly visits with nurses; biannual visits with physi-
cians; and elective visits with geriatricians, psychiatrists, 
nephrologists, and rehabilitation physicians. Upon miss-
ing a regular visit, patients were contacted by telephone.
The primary endpoints were all-cause death and the 
composite of all-cause death or HF-related hospitaliza-
tion. Fatal events were identified from electronic clinical 
records, and by contacting the patients’ relatives when 
necessary. When verification was required, data were 
compared with records stored in the databases of the 
Catalan and Spanish health systems. Events were adjudi-
cated by two of the authors (EE and JL), and by clinical 
and research nurses.
Each subject gave their written informed consent prior 
to participation. The study protocol was approved by the 
Clinical Research Ethics Committee of our institution, 
was designed in accordance with the principles outlined 
in the 2013 revision of the Declaration of Helsinki of 
1975 [11].
Blood extraction and processing
Blood samples of  ~  3  ml were collected into EDTA 
tubes via standard forearm venipuncture performed 
between 9:00  a.m. and 11:00  a.m., and were processed 
within 4  h after collection. Samples were collected at 
two time-points: at baseline (n = 101) and at the 1-year 
follow-up (n = 54) (Additional file 1: Table S1). Samples 
from the 1-year follow-up were unavailable due to death 
(7 patients), technical issues (10 patients), or patient’s 
unwillingness to repeat sampling (30 patients). Sam-
ples and data from patients included in this study were 
processed and collected by the IGTP-HUGTP Biobank 
integrated in the Spanish National Biobanks Network 
of Instituto de Salud Carlos III (PT13/0010/0009) and 
Tumour Bank Network of Catalonia. All laboratory 
measurements were performed by staff blinded to the 
patients’ clinical characteristics.
Flow–FISH
Blood samples were first lysed by a 10-min incubation 
with PharmLyse solution (BD Bioscience, San Diego, CA, 
USA), and then the cell concentration was measured by 
flow cytometry using Perfect-Count beads (Cytognos, 
Salamanca, Spain). In a 15-min incubation at room tem-
perature (RT), 1 ×  106  cells were stained with titrated 
amounts of the following antibodies: CD86-BV605, 
CD14-BV785 (Biolegend, San Diego, CA, USA), CD16-
BV421, and CD15-AlexaFluor647 (BD Biosciences). Next, 
these cells were fixed with 6  mM bis(sulfosuccinimidyl)
suberate (Sigma-Aldrich Química SL, Madrid, Spain) for 
30 min at 2–8 °C. The reaction was quenched using 1 M 
Tris buffer (pH 8.0) for 15 min at RT. Then the residual 
red blood cells were removed by incubation with FACS 
lysing solution (BD Biosciences) for 7 min at RT.
FISH was performed using the Telomere PNA kit 
(Dako, Glostrup, Denmark) following the manufac-
turer’s instructions. The human 4-year old Caucasian 
female acute lymphoblastic leukemia 1301 cell line 
from the Health Protection Agency Culture Collections 
(HPACC) was used with each sample as an internal con-
trol. The 1301 cell line was previously cultured according 
to HPACC recommendations in RPMI 1640 (Gibco, Life 
Technologies, Grand Island, NY) with 10% fetal bovine 
serum (Sigma-Aldrich Química SL), penicillin, strepto-
mycin, and glutamine (Gibco, Life Technologies). After 
purchase of the 1301 cell line, subsequent cells were 
obtained from four passages after reaching a maximum 
of 1 ×  106  cells viable cells/ml in culture; cells with the 
same passage number were aliquoted in large numbers 
and stored at − 196 °C until use. Samples were acquired 
by flow cytometry, with up to 10,000 monocytes col-
lected per sample. We performed correction for DNA 
ploidy of the blood sample vs. the internal control as pre-
viously described [12].
All samples were acquired on a Fortessa SORP flow 
cytometer (BD Biosciences) equipped with four lasers 
(100-mW 488  nm, 150  mW 532  nm, 50  mW 405  nm, 
and 100 mW 640 nm) using sample acquisition software 
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FACSDiva v6.2 (BD Biosciences) and analyzed with 
FlowJo vX (Tree Star, Inc, Ashland, OR). We performed 
routine daily quality control tests with Cytometer Setup 
& Tracking Beads (BD Biosciences) in accordance with 
the manufacturer’s instructions. Daily QC control of 
6-peak Rainbow Calibration Particles (BD Biosciences) 
was used for Flow-FISH MFI standardization to reach 
initial target MFI values. We initially gated for G0/G1 
cells of both leukocyte subsets and 1301 cells based on 
DNA content, and then by scatter properties. Mono-
cytes were sequentially identified using a CD86 vs. 
CD16 plot, followed by a CD15 vs. CD16 plot to gate 
out neutrophils. Next, the gated monocytes were ana-
lyzed for CD14 and CD16 expression. Clumped cells 
were excluded using a plot of propidium iodide (PI) 
area vs. PI width. Finally, each subset of monocytes and 
internal control cells was displayed on a plot compris-
ing the FITC-labeled PNA probe on PI (B695-A) vs. 
the PNA probe (B515-A), and the median fluorescence 
intensity (MFI) of the PNA probe was measured.
The relative TL value for each monocyte subset was 
calculated as the ratio between the MFI of each sub-
set and the MFI of the control cells. Corrections were 
made for the DNA index of G0/G1 cells, as previously 
described [13].
Statistical analysis
Categorical variables are expressed as percentages. For 
continuous variables, data distributions were assessed 
using normal Q–Q plots, and data are expressed as 
mean and (SD) for normally distributed data, or as 
median and (quartiles Q1–Q3) for non-normally dis-
tributed data. Between-group differences were assessed 
using Student’s t test and ANOVA with post hoc 
Scheffe analysis. To assess correlations among the TL of 
the different monocyte subsets, and between the mean 
TL of all monocytes and clinical variables, we used the 
Pearson or Spearman rho correlation test, as appro-
priate. Comparison between mean TL between base-
line and 1-year samples were performed with t test for 
paired data.
We additionally performed univariate Cox regression 
analyses with all-cause death and the composite end-
point as the dependent variables, and with the mean 
TL for monocytes as a whole and for each monocyte 
subset as the independent variables. In the subgroup 
of patients for whom a 1-year follow-up blood sample 
was available, we also assessed the relative TL change 
using the formula [TL at 1 year –baseline TL]/baseline 
TL)  ×  100. Statistical analyses were performed using 
SPSS 15.0 (SPSS Inc., Chicago, IL, USA). A two-sided p 
value of < 0.05 was considered significant.
Results
Table 1 shows the clinical characteristics of the studied 
population. In general, the patients were middle-aged 
and predominantly male, showed an ischemic etiology, 
and were NYHA functional class II or III and treated 
following contemporary guidelines.
Table 1 Baseline characteristics of the study participants
Data expressed as mean ± standard deviation, median (25th–75th percentiles), 
or absolute number (percentage)
ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor 
blocker, CRT cardiac resynchronization therapy, ICD implantable cardioverter 
device, LVEF left ventricular ejection fraction, MRA mineral corticoid receptor 
antagonist, NYHA New York Heart Association
a eGFR < 60 ml/min/1.73 m2
b Hb of < 12 g/dl in women and < 13 g/dl in men
n = 101
Age (years) 65.6 ± 11.3
Male sex 76 (75.2%)
Etiology
 Ischemic heart disease 46 (45.5%)
 Dilated cardiomyopathy 18 (17.8%)
 Hypertensive cardiomyopathy 8 (7.9%)
 Alcoholic cardiomyopathy 7 (6.9%)
 Valvular disease 8 (7.9%)
 Hypertrophic cardiomyopathy 4 (4.0%)
 Other 10 (9.9%)
HF duration in months 38.7 (12.7–77.4)
LVEF 41.8% ± 12.1
NYHA functional class
 I 9 (8.9%)
 II 70 (69.3%)
 III 22 (21.8%)
Co‑morbidities
 Hypertension 74 (73.3%)
 Diabetes mellitus 50 (49.5%)
 Renal  failurea 48 (47.5%)
 Anemiab 41 (40.6%)
 Atrial fibrillation/flutter 42 (41.6%)
Obesity 31 (30.7%)
Smoker
 Current 4 (4.0%)
 Past 66 (65.3%)
Treatments
 ACEI/ARB 89 (88.1%)
 Beta‑blockers 93 (92.1%)
 MRA 63 (62.4%)
 Loop diuretics 81 (80.2%)
 Digoxin 21 (20.8%)
 Ivabradine 19 (18.8%)
 Statins 86 (85.1%)
 ICD 3 (3.0%)
 CRT 16 (15.8%)
Page 4 of 8Teubel et al. J Transl Med  (2018) 16:35 
Within this cohort of HF patients, we meas-
ured three monocyte subsets—referred to as classi-
cal  (CD14++CD16−), intermediate  (CD14++CD16+), 
and nonclassical  (CD14+CD16++)—along with their 
respective TLs. The coefficient of variation of the intra-
assay for duplicates was 5.08% for monocyte popula-
tion with minor differences between subsets. Across 
all runs, inter-assay coefficient of variation was 71.82% 
for unprobed and 22.81% for probed, similar to previ-
ously described measurements by other groups [14]. 
Figure  1 shows a representative TL analysis of a whole-
blood sample from a patient with HF. Collectively, we 
found that the TL values were highly correlated between 
the different monocyte subsets:  CD14++CD16+ vs. 
Fig. 1 Representative flow‑FISH analysis of TL in monocyte subsets from an ambulatory patient with HF. Cells were previously selected by G0/
G1 DNA Content, scatter properties and CD86 and CD15 markers for monocytes and 1301 cell line selection as described in Materials and 
methods (data not shown). Monocyte subsets were analyzed based on their CD14 and CD16 expression (a: 1.  CD14++CD16−; 2.  CD14++CD16+; 
3.  CD14+CD16+). Scatter properties of 1301 cell line and gating was shown in b. Hybridization of FITC‑labeled Telomere Probe (PNA; color filled 
histograms) and control (without probe; empty histograms) in the three existing monocyte subsets and internal reference control 1301 cell line c. 
The relative TL value for each monocyte subset was finally calculated as the ratio between the MFI of each subset and the MFI of the control cells. 
Corrections were also made for the DNA index of G0/G1 cells
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 CD14++CD16−, R = 0.95, p < 0.001;  CD14++CD16+ vs. 
 CD14+CD16++, R = 0.90, p < 0.001; and  CD14++CD16− 
vs.  CD14+CD16++, R = 0.89, p < 0.001. Table 2 shows TL 
at baseline and at the 1-year follow-up, as well as the per-
cent change, for the whole-blood sample of monocytes 
and for each monocyte subset. Within the subgroup 
of patients for whom blood samples were available for 
both time-points, we found statistically significant ~ 22% 
attrition of mean monocyte TL (11.1 ± 3.3 vs. 8.3 ± 2.1, 
p  <  0.001). Mean monocyte TL change was –22% ±  20 
(Fig.  2 and Table  2). Monocyte TL reduction occurred 
in 96.3% of patients (ranging from −  3.1 to −  66.7%); 
in 28 of these patients (51.9%) monocyte TL reduction 
was ≥ − 20%. TL at baseline, TL at the 1-year follow-up, 
and the change in TL over 1  year did not significantly 
differ between the monocyte subsets (all p values > 0.1). 
In particular, there was no difference in TL attrition 
between genders (− 23.5 ± 14.4 and − 21.4 ± 22.5% in 
women and men, respectively). Furthermore no relation-
ship between TL attrition and age (< 70 years vs. older), 
sex, ischemic etiology, presence of diabetes mellitus or 
HF duration (< 48 months vs. longer) was found.
Mean monocyte TL was not significantly related to any 
demographic or clinical characteristics, except for the 
presence of atrial fibrillation (p = 0.01) while a tendency 
to inverse correlation was observed with age (p =  0.09) 
(Table  3). Over the mean follow-up of 2.3 ±  0.6  years, 
17 patients died, 17 required hospital admission due to 
HF, and 29 suffered the composite end-point of death or 
HF hospitalization. Table 4 shows Cox regression analy-
ses for all-cause death and for the composite end-point 
of all-cause death or HF hospitalization. These outcomes 
were not associated with baseline TL or with change in 
TL over 1 year.
Discussion
The results of this longitudinal study revealed that TL 
significantly declined (by ~ 22%) within a year in circulat-
ing monocytes from patients with HF. Our data did not 
indicate that TL was correlated with various monocyte 
subsets or with HF outcomes. To our knowledge, this is 
the first study to describe the course of telomere length 
change within a well-characterized cohort of patients 
with HF using simultaneous flow-FISH.
Telomere biology is linked to aging and age-associated 
pathologies, and preliminary data from cross-sectional 
studies reveal shorter telomeres in HF patients compared 
to healthy age- and gender-balanced controls, based on 
measurements in circulating leukocytes using a con-
ventional qPCR method [5]. Moreover, TL is reportedly 
associated with the severity of HF symptoms and out-
come [5, 15], and with worse renal function in subjects 
with HF, which is a powerful predictor of outcome [16, 
17]. While TL is usually measured in leukocytes, it has 
also been evaluated in cardiac tissue from patients with 
Table 2 Telomere lengths at baseline and at 1 year
Data expressed as mean ± standard deviation
Baseline n = 101
Monocytes, whole 10.3 ± 3.3
 CD14++CD16− 10.5 ± 3.6
 CD14++CD16+ 10.1 ± 3.3
 CD14+CD16++ 10.3 ± 3.1
1 year N = 54
Monocytes, whole 8.3 ± 2.1
 CD14++CD16− 8.3 ± 2.2
 CD14++CD16+ 8.4 ± 2.3
 CD14+CD16++ 8.3 ± 2.1
%, Δ N = 54
Monocytes, whole − 22 ± 20
 CD14++CD16− − 25 ± 20
 CD14++CD16+ − 19 ± 23
 CD14+CD16++ − 21 ± 22
Fig. 2 Scatter dot plot with mean line (horizontal bar) graphic of 
relative telomere lengths at baseline and at 1 year. N = 54
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HF [18]. There remains a need for large, prospective, lon-
gitudinal studies to acquire more in-depth insights into 
the relationship between TL and HF [2]. Herein, we used 
a novel flow-FISH method to specifically determine TL 
attrition in circulating monocyte subsets [8].
All previous studies of TL in HF have been cross-sec-
tional in design, and thus have not provided information 
about possible changes in TL over time or whether any 
such changes are related to outcomes. Our current report 
provides the first evidence of accelerated telomere ero-
sion in the monocytes of patients with HF over 1  year. 
In our study, 96.3% of patients with HF showed shorten-
ing of TL at the 1-year follow-up. While this proportion 
is similar to that observed in general population stud-
ies [19], the rate of decline in our cohort is significantly 
higher than in normal individuals. Indeed, over 50% of 
the patients exhibited a telomere attrition exceeding 
− 20% at the 1-year follow-up. The MRC National Survey 
of Health and Development (NSHD, also known as the 
1946 British Birth Cohort) exquisitely reported longitu-
dinal measures of telomere length in a large cohort com-
prising mainly cardiovascular disease-free participants. 
In this cohort of healthy individuals, telomere length 
shortening over ten years was  ~ −  2%, as measured by 
real-time PCR [19].
It is beyond the scope of this study to determine exactly 
why telomeres shorten faster in patients with HF. How-
ever, oxidative stress and inflammation are considered 
the most important factors contributing to telomeric 
DNA loss [6], which in turn may favor the development 
of structural tissue damage. It is postulated that shorter 
TL may be an irremediable intracellular mechanism 
facilitating or even causing HF. Indeed, experimental 
data suggest that telomere shortening partly mediates 
apoptosis in HF [18]. Furthermore, telomere attrition 
may lead to increased levels of dysfunctional senescent 
cells (e.g., circulating monocytes) in tissues and organs, 
potentially explaining the lower threshold for expressing 
clinical manifestation of disease [2]. A biomarker’s value 
is largely determined by its capacity to reflect prognosis 
or change in disease progression; therefore, we followed 
patients for a mean of 2.3 years. Our data showed no cor-
relation between the rate of telomere attrition and the 
primary endpoints, suggesting that telomere shortening 
rate may not be a clinically useful measurement or a via-
ble surrogate marker of disease progression. On the other 
hand, it is possible that a longer observation period or a 
larger sample may be required to evaluate these clinical 
endpoints.
The presented findings also revealed that monocyte TL 
was associated with atrial fibrillation. Recent investiga-
tions of the relationship between TL and atrial fibrillation 
Table 3 Baseline monocyte Telomere lengths according 
to demographic and clinical characteristics
Data expressed as mean ± standard deviation, median (25th–75th percentiles), 
or absolute number (percentage). R and Rho according to Pearson and 
Spearman correlation, respectively
LVEF left ventricular ejection fraction, NYHA New York Heart Association
§ Scheffe post hoc analyses did not reveal any statistical difference between 
individual items
a eGFR < 60 ml/min/1.73 m2
b Hb of < 12 g/dl in women and < 13 g/dl in men
n = 101 p
Age (years) R = − 0.17 0.09
Sex 0.44
 Male 10.2 ± 2.9
 Female 10.7 ± 4.2
Etiology 0.90§
 Ischemic heart disease 10.4 ± 3.5
 Dilated cardiomyopathy 10.3 ± 4.4
 Hypertensive cardiomyopathy 10.5 ± 3.0
 Alcoholic cardiomyopathy 9.5 ± 1.8
 Valvular disease 9.1 ± 1.8
 Hypertrophic cardiomyopathy 11.3 ± 3.3
 Other 10.9 ± 2.5
HF duration in months Rho = − 0.13 0.20
LVEF R = 0.14 0.18
NYHA functional class 0.85§
 I 10.4 ± 3.5
 II 10.4 ± 3.6
 III 10.0 ± 3.3
Hypertension 0.66
 Yes 10.2 ± 3.5
 No 10.5 ± 2.3
Diabetes mellitus 0.24
 Yes 10.7 ± 3.4
 No 9.9 ± 3.1
Renal  failurea 0.31
 Yes 10.0 ± 2.8
 No 10.6 ± 3.6
Anemiab 0.23
 Yes 10.8 ± 3.1
 No 10.0 ± 3.3
Atrial fibrillation/flutter 0.01
 Yes 9.3 ± 2.6
 No 11 ± 3.5
Obesity 0.23
 Yes 10.9 ± 3.6
 No 10.1 ± 3.1
Smoker 0.48
 No 10.4 ± 3.3
 Past 10.3 ± 3.3
 Current 8.6 ± 2.4
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have produced controversial findings [20]. In the Cardi-
ovascular Health Study (CHS), Roberts et  al. [21] com-
pared patients with and without atrial fibrillation, and 
found no relationship between mean TL and atrial fibril-
lation. In contrast, Carlquist et al. [22] reported shorter 
TL in patients with atrial fibrillation, both before and 
after adjustment for age and other cardiovascular risk 
factors. However, the exact mechanism leading to shorter 
TL in patients with atrial fibrillation remains elusive.
Of note, since participants were drawn from the gen-
eral population that visited a structured HF Clinic 
located within a tertiary university hospital and our 
cohort included mainly male patients with ischemic heart 
disease, further research is needed to determine whether 
our findings can be generalized to other HF cohorts, such 
as patients with HF and preserved ejection fraction. As 
limitations, our sample size or duration of observation 
(2.3  years) seem to be insufficient to show significant 
associations between telomere shortening and the tested 
outcomes. We thus hypothesize that larger follow-up 
period and many measurement time-points will be cru-
cial to further validate our findings. However, to imple-
ment a biomarker in precision medicine, it must show 
clinical applicability in small numbers of patients, if not 
in individual subjects.
Conclusions
In summary, the present longitudinal observational study 
revealed a 22% reduction in TL over 1  year in mono-
cytes from ambulatory patients with HF. Baseline TL and 
change in TL were not significantly associated with out-
comes; therefore, the change in TL is not likely to be a 
useful biomarker of HF progression.
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